The estimated Net Worth of Joseph P Slattery is at least $8.12 Milion dollars as of 13 November 2023. Mr. Slattery owns over 2,400 units of Morphic Inc stock worth over $516,671 and over the last 11 years he sold MORF stock worth over $7,337,093. In addition, he makes $262,516 as Independent Director at Morphic Inc.
Sign up
Mr. Slattery MORF stock SEC Form 4 insiders trading
Joseph has made over 23 trades of the Morphic Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 2,400 units of MORF stock worth $49,440 on 13 November 2023.
The largest trade he's ever made was selling 699,486 units of Morphic Inc stock on 25 June 2018 worth over $3,784,219. On average, Joseph trades about 59,935 units every 72 days since 2014. As of 13 November 2023 he still owns at least 9,066 units of Morphic Inc stock.
You can see the complete history of Mr. Slattery stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joseph Slattery biography
Joseph P. Slattery CPA serves as Independent Director of the Company. From October 2013 through December 2019, he served as Executive Vice President and Chief Financial Officer of TransEnterix, Inc., a medical device company. Mr. Slattery served as Executive Vice President and Chief Financial Officer at Baxano Surgical Inc., a minimally invasive spinal surgery company, from April 2010 to September 2013. From February 1996 to August 2007, he served in finance and accounting roles including Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corp., a molecular diagnostics company acquired by Qiagen, N.V. in 2007. Currently, he serves on the boards of directors of Replimune Group, Inc. and certain private companies. Mr. Slattery earned a B.S. in Accounting from Bentley University and is a certified public accountant.
What is the salary of Joseph Slattery?
As the Independent Director of Morphic Inc, the total compensation of Joseph Slattery at Morphic Inc is $262,516. There are 9 executives at Morphic Inc getting paid more, with Timothy Springer having the highest compensation of $1,260,500.
How old is Joseph Slattery?
Joseph Slattery is 55, he's been the Independent Director of Morphic Inc since 2019. There are 4 older and 15 younger executives at Morphic Inc. The oldest executive at Morphic Holding Inc is Dr. Timothy A. Springer Ph.D., 73, who is the Founder, Independent Director & Member of Scientific Advisory Board.
What's Joseph Slattery's mailing address?
Joseph's mailing address filed with the SEC is C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM, MA, 02451.
Insiders trading at Morphic Inc
Over the last 5 years, insiders at Morphic Inc have traded over $69,316,197 worth of Morphic Inc stock and bought 3,360,997 units worth $101,882,696 . The most active insiders traders include Plc Gsk, Holdings A/S Novo oraz Timothy A Springer. On average, Morphic Inc executives and independent directors trade stock every 13 days with the average trade being worth of $2,254,353. The most recent stock trade was executed by Bruce Rogers on 8 July 2024, trading 20,000 units of MORF stock currently worth $86,400.
What does Morphic Inc do?
oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
What does Morphic Inc's logo look like?
Complete history of Mr. Slattery stock trades at Asensus Surgical Inc, Replimune Inc oraz Morphic Inc
Morphic Inc executives and stock owners
Morphic Inc executives and other stock owners filed with the SEC include:
-
Timothy Springer,
Founder, Independent Director -
Alexey Lugovskoy,
Chief Development Officer -
Dr. Praveen P. Tipirneni M.D.,
CEO, Pres & Director -
William DeVaul,
General Counsel, Secretary -
Praveen Tipirneni,
President, Chief Executive Officer, Director -
Dr. Marc Schegerin M.B.A., M.D.,
CFO & COO -
Bruce Rogers,
Chief Scientific Officer -
Vikas Goyal,
Independent Director -
Gustav Christensen,
Independent Chairman of the Board -
Joseph Slattery,
Independent Director -
Otello Stampacchia,
Independent Director -
Norbert Bischofberger,
Independent Director -
Amir Nashat,
Independent Director -
Dr. Timothy A. Springer Ph.D.,
Founder, Independent Director & Member of Scientific Advisory Board -
Nilesh Kumar,
Independent Director -
Peter Linde,
Chief Medical Officer -
Robert Farrell,
Senior Vice President - Finance, Chief Accounting Officer -
Marc Schegerin,
Chief Financial Officer, Chief Operating Officer -
Adrian S. Ray Ph.D.,
Sr. VP and Head of Biology & Translation -
Blaise Lippa,
Sr. VP of Molecular Discovery -
William D. DeVaul Esq.,
Gen. Counsel & Sec. -
Dr. Bruce N. Rogers,
Chief Scientific Officer -
Robert E. Farrell Jr., CPA, CPA,
Sr. VP of Fin./Operations & Chief Accounting Officer -
Susannah Gray,
-
Nisha Nanda,
-
Martin Edwards,
-
Holdings A/S Novo,
10% owner -
Plc Gsk,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Simon Peter Cooper,
CMO